Literature DB >> 24397395

Cushing's syndrome secondary to ectopic ACTH secretion from carcinoid tumor within an ovarian mature teratoma: a case report and review of the literature.

Baoyou Huang1, Xueqing Wu, Qing Zhou, Yan Hu, Hongqin Zhao, Hua Zhu, Qian Zhang, Feiyun Zheng.   

Abstract

A 46-year-old woman with Cushing's syndrome secondary to ectopic adrenocorticotropic hormone (ACTH) secretion caused by primary ovarian mature teratoma with carcinoid components was presented in our case. The patient manifested sustained hypercortisolemia without circadian rhythm and a lack of suppression of either low-dose dexamethasone suppression test (LDDST) or high-dose dexamethasone suppression test (HDDST). There was no evidence of a pituitary mass or secretion of other hormones. After careful clinical evaluation, no other tumor masses were found. Resection of the ovarian tumors led to sharp reduction of serum ACTH and cortisol concentrations. Immunohistochemistry showed positivity in CgA, Syn, CK, NSE. To the best of our knowledge, there are rare reports of an ACTH-secreting carcinoid components located in an ovarian mature teratoma, and bilateral ovarian mature teratoma makes it rarer.

Entities:  

Mesh:

Year:  2014        PMID: 24397395     DOI: 10.3109/09513590.2013.871518

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  5 in total

1.  Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.

Authors:  Jennifer B Permuth; Ailith Pirie; Y Ann Chen; Hui-Yi Lin; Brett M Reid; Zhihua Chen; Alvaro Monteiro; Joe Dennis; Gustavo Mendoza-Fandino; Hoda Anton-Culver; Elisa V Bandera; Maria Bisogna; Louise Brinton; Angela Brooks-Wilson; Michael E Carney; Georgia Chenevix-Trench; Linda S Cook; Daniel W Cramer; Julie M Cunningham; Cezary Cybulski; Aimee A D'Aloisio; Jennifer Anne Doherty; Madalene Earp; Robert P Edwards; Brooke L Fridley; Simon A Gayther; Aleksandra Gentry-Maharaj; Marc T Goodman; Jacek Gronwald; Estrid Hogdall; Edwin S Iversen; Anna Jakubowska; Allan Jensen; Beth Y Karlan; Linda E Kelemen; Suzanne K Kjaer; Peter Kraft; Nhu D Le; Douglas A Levine; Jolanta Lissowska; Jan Lubinski; Keitaro Matsuo; Usha Menon; Rosemary Modugno; Kirsten B Moysich; Toru Nakanishi; Roberta B Ness; Sara Olson; Irene Orlow; Celeste L Pearce; Tanja Pejovic; Elizabeth M Poole; Susan J Ramus; Mary Anne Rossing; Dale P Sandler; Xiao-Ou Shu; Honglin Song; Jack A Taylor; Soo-Hwang Teo; Kathryn L Terry; Pamela J Thompson; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen; Lynne R Wilkens; Stacey Winham; Yin-Ling Woo; Anna H Wu; Hannah Yang; Wei Zheng; Argyrios Ziogas; Catherine M Phelan; Joellen M Schildkraut; Andrew Berchuck; Ellen L Goode; Paul D P Pharoah; Thomas A Sellers
Journal:  Hum Mol Genet       Date:  2016-07-04       Impact factor: 6.150

Review 2.  Severe Cushing's syndrome due to small cell prostate carcinoma: a case and review of literature.

Authors:  M S Elston; V B Crawford; M Swarbrick; M S Dray; M Head; J V Conaglen
Journal:  Endocr Connect       Date:  2017-06-05       Impact factor: 3.335

3.  Clinical Approach to Neuroendocrine Neoplasm Associated With Ovarian Teratoma.

Authors:  Marta Opalińska; Anna Sowa-Staszczak; Helena Olearska; Magdalena Ulatowska-Bialas; Aleksandra Gilis-Januszewska; Alicja Hubalewska-Dydejczyk
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

Review 4.  Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review.

Authors:  Daria Ryzhkova; Lubov Mitrofanova; Uliana Tsoy; Elena Grineva; Evgeny Schlyakhto
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-05       Impact factor: 6.055

Review 5.  Primary ovarian carcinoid: Two cases report and review of literature.

Authors:  Li-Rong Zhai; Xi-Wen Zhang; Tong Yu; Zhen-De Jiang; Dong-Wei Huang; Yan Jia; Man-Hua Cui
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.